Cannabix Technologies Applauds Canadian Task Force Report on Cannabis Legalization and its Focus on Marijuana Impaired Driving
December 14 2016 - 9:00AM
InvestorsHub NewsWire
7934 Government Road, Burnaby, B.C.,
V5A 2E2
Phone: (604) 551-7831
Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Marijuana Breathalyzer developer, Cannabix
Technologies comments on Canadian special task force report on
the future regulation of recreational cannabis in
Canada
Vancouver, BC -- December 14, 2016 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC
PINK: BLOZF) (the “Company or Cannabix”) After a preliminary
review of the findings of the Canadian special task force released
on December 13, 2016, on the future regulation of recreational
cannabis in Canada, Kal Malhi, President of Cannabix states, “We
welcome the recommendations from the Task Force members which
speaks to the urgent need to identify and approve a scientific tool
to collect court approved evidence of marijuana impaired driving.
Cannabix is developing its Cannabix Marijuana Breathalyzer to help
law enforcement and employers to enhance detection of marijuana
impaired driving offences on roads at a time when marijuana is
becoming legal in various jurisdictions. The report confirms
that marijuana impaired driving poses an increasing risk to the
public and law enforcement needs a tool that can be used at the
roadside to collect court admissible evidence of impairment at the
time of the test. The report is concrete validation of the
work we have been doing at Cannabix in developing our Cannabix
Marijuana Breathalyzer and being a leader and early mover in
this space.”
The Task Force agrees with experts in law
enforcement that impaired driving is a serious issue that exists
currently and requires immediate action to protect public
safety. The report also confirms that the level of THC in
bodily fluids cannot be used to reliably indicate the degree
of impairment or crash risk. In addition, the Company notes
and applauds the following specific recommendations to provincial
Ministers across Canada, which include:
Determining whether to establish a per se limit as part of a
comprehensive approach to cannabis-impaired driving and re-examine
per se limits should a reliable correlation between THC levels and
impairment be established;
Supporting the development of an appropriate roadside drug
screening device for detecting THC levels, and invest in these
tools;
Investing in baseline data collection and ongoing surveillance
and evaluation in collaboration with provinces and
territories.
Cannabix Technologies is working to develop a rigorous trial with
expedited ethics approval to begin detailed scientific trial
testing of the Cannabix Marijuana Breathalyzer. This trial is
intended to compare the Cannabix Marijuana Breathalyzer utilizing
breath samples with correlated blood samples. The Company plans to
use key metrics and guidance from Drugs and Driving Committee
(DDC), which is an advisory body to the Canadian Department of
Justice on issues relating to drug-impaired driving and has been
given a mandate to develop reports regarding drugs that are
proposed for zero-tolerance and per se legislation, including
cannabis/THC.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a leader in
marijuana breathalyzer development for law enforcement and the
workplace. Cannabix has established breath testing technologies in
the pursuit of bringing durable, portable hand-held tools to market
to enhance detection of marijuana impaired driving offences on
roads at a time when marijuana is becoming legal in many global
jurisdictions. Cannabix is working to develop drug-testing devices
that will detect THC- the psychoactive component of marijuana that
causes intoxication- using breath samples. In particular, Cannabix
is focused on developing breath testing devices for detection of
recent use of THC, in contrast to urine testing for THC metabolite
that requires an invasive collection and reflects use days or even
weeks earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace where
intoxication by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains
forward-looking information that involves various risks and
uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company’s plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (v) the ability of the Company to develop and market
its future product; and (vi) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Sep 2023 to Sep 2024